HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $9 Price Target

Aclaris Therapeutics, Inc. +0.81%

Aclaris Therapeutics, Inc.

ACRS

1.24

+0.81%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ: ACRS) with a Buy and maintains $9 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via